47 results about "Radiation Enteritis" patented technology

The present invention relates to novel conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds are useful as therapeutics for a range of gastrointestinal disorders, in particular those in which suppression or inhibition of the migrating motor complex (MMC) is effective or malfunction of gastric motility or increased motilin secretion is observed, such as hypermotilinemia, imitable bowel syndrome, dyspepsia, including gallbladder dyspepsia, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, acute infectious diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, functional gastrointestinal disorders, chemotherapy-induced nausea and vomiting (emesis), post-operative nausea and vomiting, cyclic vomiting syndrome and functional vomiting. Accordingly, methods of treating such disorders with such macrocyclic compounds and pharmaceutical compositions thereof are also provided in addition to methods of modulating the migrating motor complex.

An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysis and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

The enteric trilobate factor oral preparation is characterized by that it contains enteric trilobate factor as pharmacodynamic active component, also contains enteric trilobate factor activating agent and enteric trilobate factor protecting agent, so that it can be used for curing the diseases of ulcer of digestive tract, radiation enteritis, chronic gastritis and enteritis.

The invention relates to a method of using an S1P receptor conditioning agent to prevent and/or cure stomach and intestine organization damages caused by ionising radiation, concretely to individually use, or combined with other treatment methods, the S1P receptor conditioning agent to prevent and/or cure intestinal radiation sickness and radiation enteritis caused by tumour radiation treatment.

The invention relates to a Chinese medicinal preparation used for treating radiation enteritis. The Chinese medicinal preparation used for treating the radiation enteritis comprises the following effective raw material components: all-grass of broadleaf ainslaea, humifuse euphorbia herb, melastoma dodecandrum, calamint, lotus petiole, gynostemma pentaphyllum, chinese amphibious knotweed rhizome, meadowrue root and rhizome, gray polypody, sea-buckthorn, clematis finetiana, cactus, polygonum hydropiper, sago seed, fortune paulownia flower and screwtree root. The Chinese medicinal preparation used for treating the radiation enteritis has the effects of tonifying qi, nourishing yin, removing heat to promote salivation, astringe intestine to stop bleeding and astringing to stop pain and has a good treatment effect on radiation enteritis caused by a radioactive factor; the selected medicinal raw materials are available; the Chinese medicinal preparation used for treating the radiation enteritis is easy to make, low in cost and obvious in curative effect, can treat both symptoms and root causes and has no toxic and side effect; dialectical treatment is carried out according to a clinical disease, and the total effective rate of treatment on the radiation enteritis can be up to 98%.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a composition for improving or treating radiation enteritis and a preparation method and application thereof. The medicine composition for improving or treating radiation enteritis is prepared from the following crude drugs in parts by weight: 12 to 18 parts of purslane herb, 8 to 12 parts of flos sophorae immaturus, 8 to 12 parts of dark plum fruit, 2 to 5 parts of cinnamomum cassia, 12 to 18 parts of fructus hippophae, 2 to 6 parts of endothelium corneum gigeriae galli, and 8 to 12 parts of poria cocos. The composition has the advantages that the effect of treating the radiation enteritis is realized; the radiation enteritis symptoms due to radiotherapy in pelvic cavity and perineum, such as diarrhea and abdominal pain, mucous bloody stool and tenesmus, can be greatly relieved; the composition is suitable for patients with radiation enteritis to take in the period of chemoradiotherapy; especially, when the composition is prepared into the traditional Chinese medicine solid beverages, the preparing is convenient, the mouth feel is good, and the preparation technology is simple.

The invention provides application of propylene glycol to medicine for preventing intestinal type radiation disease and radiation enteritis. According to the application disclosed by the invention, the propylene glycol is firstly applied to the field of radiation protection research, and the research proves that compared with former prevention application, the propylene glycol has an obvious experimental therapeutic effect on acute radiation injury of intestinal tracts and has curative effects on intraperitoneal injection and oral administration; moreover, a radiation protection mechanism of the propylene glycol is possibly related with removal of hydroxyl radicals through the propylene glycol and alleviation of intestinal cell DNA injuries. At present, the phenomenon that gastrointestinaltissue injuries or the radiation enteritis occurs when the propylene glycol is applied to prevention of ionizing radiation or tumor radiotherapy is not reported yet.

The present invention provides a method for establishing an animal model of radiation-induced colorectal inflammation. The method comprises the following steps: mice are randomly divided into two large groups; the mice are normal fed for 1-2 weeks to enable the mice to be adapted to a new living environment; body positions of the mice during irradiation are simulated and an average value is taken;a radiotherapy plan is developed; depending on different group designs, a single large dose radiation is conducted using different doses of gradient rays; and severity of colorectal tissue lesions isassessed. Combining clinical practices, a common therapeutic ray (6MV X ray) used by a medical linear accelerator can better simulate radioactive colorectal injury lesion process of clinical radiotherapy side reactions, and besides, the method is low in animal mortality and simple and easy to repeat, provides an experimental basis for studying the radioactive colorectal injury, is convenient forfurther studying mechanism of the radioactive colorectal injury and guiding clinical medication, closer to clinical practice and more conducive to studying course mechanism of radiation enteritis anddrug development, and can also further expand use of a prevention and treatment technology applied in the radiation enteritis.

The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment of, for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, ladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof.

The invention discloses a medicine for treating radiation enteritis and a preparation method and application of the medicine. The medicine is composed of the following raw materials including, by weight, 3-7 parts of levamisole, 11-19 parts of bromhexine, 5-13 parts of taurine and 1-5 parts of calcium pyruvate. The levamisole, the bromhexine and the calcium pyruvate are mixed and added into deionized water, and the mixture is heated to 75 DEG C to 77 DEG C and stirred for 38 min to 40 min to prepare the mixture A; the mixture A and the taurine are mixed and subjected to ultrasonic treatment at 58 DEG C for 25 min, the ultrasonic power is 900W, then the mixture is stirred to dry at 63 DEG C, and the medicine is obtained. The medicine has the advantages of being unique in formula, low in price, safe and convenient to use, the effect of the medicine is superior to that of conventionally used western medicines, the medicine can effectively cure the junction and rectal injuries caused during radiotherapy and is high in cure rate, quick in effect and free of toxic and side effects and relapse after curing, simple in preparation process, short in production cycle low in cost and suitable for industrial production and large-scale popularization, and the raw materials are simple and easy to obtain.

The invention discloses a Chinese and western medicinal composition for treating radioactive enteritis, and a preparation method and application thereof. The Chinese and western medicinal composition comprises, by weight, 3-7 parts of alendronate sodium, 11-19 parts of bromhexine, 5-13 parts of taurine and 1-5 parts of calcium lactate. The preparation method includes mixing the alendronate sodium with the bromhexine and the calcium lactate, adding deionized water, increasing the temperature to 75-77 DEG C, and stirring the raw materials for 38-40 minutes to obtain a mixture A; mixing the mixture A with the taurine, performing ultrasonic treatment at the temperature of 58 DEG C for 25 minutes, and performing stirring at the temperature of 63 DEG C until drying to obtain the Chinese and western medicinal composition, wherein the ultrasonic power is 900W. The Chinese and western medicinal composition has a unique formula and low price, is safe and convenient, has better effect than regularly-used western medicine, can effectively treat colon and rectum injuries caused by radiotherapy, has high cure rate and quick action and is free from toxic and side effect; recurrence of the radioactive enteritis is avoided after curing; the preparation process is simple, raw materials are simple and easy to get, production cycle is short, cost is low, and the Chinese and western medicinal composition is suitable for industrial production and large-scale popularization.

The invention discloses a composition treating colorectal cancer and applications of medicines treating colorectal cancer. The composition comprises the following ingredients containing treatment effective doses: any one or two of ground beetle and gekko swinhonis seu japonicus, any one or two of peach seeds and curcuma rhizome, any one or two of radix sophorae flavescentis and patrinia herb, any one or two of smilax glabra and cortex moutan, any one or two of garden burnet and barbat skullcap, any one or two of sophora flowers and pseudobulubs cremastrae seu pleiones, and any one or two of dandelion and manyleaf paris rhizome. The composition is provided in an ingredient ratio less than a poisonous dose. The composition also can comprise coix seeds or radix scrophulariae, and is used combined with chemotherapeutants further. The composition is suitable for colorectal cancer patients with current known various symptoms, can inhibit precancerous lesions effectively, improves mucous bloody stool of intestinal cancer patients, relieves radiation enteritis, raises life quality of intestinal cancer patients and provides a forward life expectancy with definite and objective therapeutic effects for intestinal cancer patients.

The invention discloses a traditional Chinese medicine composition for treating radiation enteritis. The traditional Chinese medicine composition is prepared from herb of shiny cinquefoil, radix scutellariae, ashgrey loosestrife herb, fructus forsythiae, fructus aurantii, radix aucklandiae, scorzonera subacaulis and licorice roots. The invention also discloses a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is reasonable in component compatibility, can clear heat, promote diuresis, promote qi circulation, relieve pain, calm theliver and regulate qi, has no obvious liver and kidney toxicity, and is suitable for being applied to radiation enteritis treatment.

The invention belongs to the field of biological medicine, and relates to application of a PDGF inhibitor in preparation of medicines for treating intestinal inflammation diseases, in particular to application of a PDGFR signal pathway inhibitor in preparation of medicines for treating radiation enteritis. It is found for the first time that both ligands and receptors of PDGFR signal pathways arehighly expressed in intestinal tissues with radiation enteritis. Furthermore, intestinal injuries caused by radiotherapy are effectively relieved by inhibiting the PDGFR signal pathways. The inventionprovides a brand-new idea for treating radiation enteritis.

The invention discloses a medicine for treating radiation enteritis and a preparation method thereof. The medicine is composed of the following raw materials in parts by weight: 3-7 parts of rabeprazole, 11-19 parts of radix astragali extract, 5-13 parts of taurine and 1-5 parts of calcium pyruvate. The preparation method comprises the following steps: mixing the rabeprazole, radix astragali extract and calcium pyruvate, adding deionized water, heating to 75-77 DEG C, and stirring for 38-40 minutes to obtain a mixture A; mixing the mixture A with the taurine, carrying out ultrasonic treatment at 58 DEG C under the ultrasonic power of 900W for 25 minutes, and stirring at 63 DEG C to a dry state, thereby obtaining the medicine. The medicine for treating radiation enteritis has the characteristics of unique composition and low price, is safe and convenient, and has better effects than the conventional western medicine. The medicine for treating radiation enteritis can effectively cure the colon and recta injuries caused by radiotherapy, and has the advantages of high cure rate, quick effect taking, no toxic or side effect, and no relapse after curing. The preparation method has the advantages of simple preparation technique, simple and accessible raw materials, short production cycle and low cost, and is suitable for industrial production and large-scale popularization.

The invention provides an application of liriodendrin in a medicine for treating radiation enteritis. The invention finds that the liriodendrin has anti-inflammatory and anti-apoptosis effects in radiation enteritis, and through nerve sphingolipid pathway detection, it is found that the liriodendrin can reduce the expression of Cer, Cer1P and S1P, which prompts that the liriodendrin has anti-inflammatory and anti-apoptosis effects on radiation enteritis, and the liriodendrin can inhibit the expression of proinflammatory cytokines (IL-6 and TNF-alpha) in the intestinal tract of a mouse with radiation enteritis. Besides, the liriodendrin can effectively inhibit expression of intestinal tissues p-NF-kB of mice suffering from radiation enteritis, and the liriodendrin can also reduce the number of neutrophils in the intestinal tissues, which shows that the liriodendrin has an anti-inflammatory effect in radiation enteritis. A theoretical basis is provided for deep research on pathogenesis of radiation enteritis and development of new drugs, so that a scientific basis is provided for clinical treatment of radiation enteritis by using liriodendrin, and a more beneficial treatment scheme can be provided for patients with radiation enteritis.

The invention provides application of costus lactone and a derivative thereof in preparation of a medicine for preventing and/or treating intestinal injury, and belongs to the technical field of chemical medicines. Specifically, the invention provides application of a compound shown as a formula I, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof in preparation of a medicine for preventing and/or treating intestinal injury, and R1 and R2 are respectively and independently selected from C1-C8 alkyl groups. Research finds that costus lactone has a protective effect on intestinal epithelial cell injury, especially radiation-induced intestinal epithelial cell injury, can effectively prevent and/or treat intestinal injury, especially radiation intestinal injury, especially radiation enteritis, can prolong the survival rate and improve the life quality of a patient, and has good safety within an effective dose. The costus lactone can be used for preparing medicines for preventing and/or treating intestinal injury, especially radioactive intestinal injury, and has a good application prospect.